Measuring Costs of Cardiovascular Disease Prevention for Patients with Familial Hypercholesterolemia in Administrative Claims Data
High Blood Pressure & Cardiovascular Prevention · 2024
DOI: 10.1007/s40292-024-00624-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift High Blood Pressure & Cardiovascular Prevention, 2024. Verfasst von Lauren E Passero und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmaceutical Outcomes and Policy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. laurl4@email.unc.edu. Hauptthemen laut MEDLINE: Hyperlipoproteinemia Type II, Drug Costs, Administrative Claims, Healthcare, Cardiovascular Diseases. Die Arbeit nennt 13 Literaturangaben. Gefördert von: NCATS NIH HHS, National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
INTRODUCTION: Familial hypercholesterolemia is a common genetic condition that significantly increases an individual's risk of cardiovascular events such as heart attack, stroke, and cardiac death and is a candidate for population-wide screening programs. Economic analyses of strategies to identify and treat familial hypercholesterolemia are limited by a lack of real-world cost estimates for screening services and medications for reducing cardiovascular risk in this population. METHODS: We estimated the cost of lipid panel testing in patients with hyperlipidemia and the cost of statins, ezetimibe, and PCKS9 inhibitors in patients with familial hypercholesterolemia from a commercial claims database and report costs and charges per panel and prescription by days' supply. RESULTS: The mean cost for a 90-day supply for statins was $183.33, 2.3 times the mean cost for a 30-day supply at $79.35. PCSK9 inhibitors generated the highest mean costs among medications used by patients with familial hypercholesterolemia. CONCLUSIONS: Lipid testing and lipid-lowering medications for cardiovascular disease prevention generate substantial real-world costs which can be used to improve cost-effectiveness models of familial hypercholesterolemia screening and care management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmaceutical Outcomes and Policy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. laurl4@email.unc.edu.
- Division of Pharmaceutical Outcomes and Policy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Förderung
- NCATS NIH HHS
- National Center for Advancing Translational Sciences
Zitieren
APA
Passero, L. E., & Roberts, M. C. (2024). Measuring Costs of Cardiovascular Disease Prevention for Patients with Familial Hypercholesterolemia in Administrative Claims Data. High Blood Pressure & Cardiovascular Prevention. https://doi.org/10.1007/s40292-024-00624-6
Vancouver
Passero LE, Roberts MC. Measuring Costs of Cardiovascular Disease Prevention for Patients with Familial Hypercholesterolemia in Administrative Claims Data. High Blood Pressure & Cardiovascular Prevention. 2024. doi:10.1007/s40292-024-00624-6
BibTeX
@article{Passero2024,
author = {Passero, Lauren E and Roberts, Megan C},
title = {Measuring Costs of Cardiovascular Disease Prevention for Patients with Familial Hypercholesterolemia in Administrative Claims Data},
journal = {High Blood Pressure & Cardiovascular Prevention},
year = {2024},
doi = {10.1007/s40292-024-00624-6}
}
EUVIMED